Login to Your Account

Pharma: Other News To Note

Wednesday, April 18, 2012
• Abbott, of Abbott Park, Ill., said it acquired an exclusive license for several biomarkers from Stanford University for use in developing a molecular diagnostic test to differentiate aggressive from nonaggressive prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription